Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Biagio De Angelis

Showing results (21-30 of 65) with videos related to

Pageof 7
Sort By:
Journal of Personalized Medicine|March 26, 2025
The Public Knowledge of Precision Medicine and Genomic Research: A Survey in the Aosta ValleyMatteo Mongelli, Biagio De Angelis, Valeria Delle Cave, et al.
Haematologica|April 30, 2025
Truncated form of human CD19 antigen as a suicide gene to control T-cell alloreactivity: ΔCD19Simona Manni, Laura Iaffaldano, Marika Guercio, et al.
Cancer Cell International|April 30, 2022
FGFR1 is a potential therapeutic target in neuroblastomaFlora Cimmino, Annalaura Montella, Matilde Tirelli, et al.
International Journal of Molecular Sciences|March 12, 2020
DNA Methylation Profiling for Diagnosing Undifferentiated Sarcoma with Capicua Transcriptional Receptor (<i>CIC</i>) AlterationsEvelina Miele, Rita De Vito, Andrea Ciolfi, et al.
Leukemia Research|August 19, 2007
Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rateGiuliana Alimena, Massimo Breccia, Luigia Luciano, et al.
Epigenomics|December 21, 2018
Expression profiles of exosomal miRNAs isolated from plasma of patients with desmoplastic small round cell tumorMarta Colletti, Alessandro Paolini, Angela Galardi, et al.
Genome Biology|January 29, 2021
ADAR1 is a new target of METTL3 and plays a pro-oncogenic role in glioblastoma by an editing-independent mechanismValentina Tassinari, Valeriana Cesarini, Sara Tomaselli, et al.
Leukemia Research|November 28, 2013
Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemiaConcetta Quintarelli, Biagio De Angelis, Santa Errichiello, et al.
Frontiers in Immunology|December 12, 2019
Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T CellsVinicia A Polito, Rosaria Cristantielli, Gerrit Weber, et al.
Frontiers in Oncology|November 3, 2025
Prolonged overall survival in a child with multimetastatic retinoblastoma treated with anti-GD2 monoclonal antibody dinutuximab beta: a case reportValentina Di Ruscio, Alessia Carboni, Giada Del Baldo, et al.
Pageof 7

Showing results (21-30 of 65) with videos related to

Sort By:
Pageof 7
Journal of Personalized Medicine|March 26, 2025
The Public Knowledge of Precision Medicine and Genomic Research: A Survey in the Aosta ValleyMatteo Mongelli, Biagio De Angelis, Valeria Delle Cave, et al.
Haematologica|April 30, 2025
Truncated form of human CD19 antigen as a suicide gene to control T-cell alloreactivity: ΔCD19Simona Manni, Laura Iaffaldano, Marika Guercio, et al.
Cancer Cell International|April 30, 2022
FGFR1 is a potential therapeutic target in neuroblastomaFlora Cimmino, Annalaura Montella, Matilde Tirelli, et al.
International Journal of Molecular Sciences|March 12, 2020
DNA Methylation Profiling for Diagnosing Undifferentiated Sarcoma with Capicua Transcriptional Receptor (<i>CIC</i>) AlterationsEvelina Miele, Rita De Vito, Andrea Ciolfi, et al.
Leukemia Research|August 19, 2007
Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rateGiuliana Alimena, Massimo Breccia, Luigia Luciano, et al.
Epigenomics|December 21, 2018
Expression profiles of exosomal miRNAs isolated from plasma of patients with desmoplastic small round cell tumorMarta Colletti, Alessandro Paolini, Angela Galardi, et al.
Genome Biology|January 29, 2021
ADAR1 is a new target of METTL3 and plays a pro-oncogenic role in glioblastoma by an editing-independent mechanismValentina Tassinari, Valeriana Cesarini, Sara Tomaselli, et al.
Leukemia Research|November 28, 2013
Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemiaConcetta Quintarelli, Biagio De Angelis, Santa Errichiello, et al.
Frontiers in Immunology|December 12, 2019
Universal Ready-to-Use Immunotherapeutic Approach for the Treatment of Cancer: Expanded and Activated Polyclonal γδ Memory T CellsVinicia A Polito, Rosaria Cristantielli, Gerrit Weber, et al.
Frontiers in Oncology|November 3, 2025
Prolonged overall survival in a child with multimetastatic retinoblastoma treated with anti-GD2 monoclonal antibody dinutuximab beta: a case reportValentina Di Ruscio, Alessia Carboni, Giada Del Baldo, et al.
Pageof 7